Cancer Chemotherapy and Pharmacology

, Volume 71, Issue 6, pp 1507–1520 | Cite as

Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia

  • Siobhan Hayes
  • Paul N. MuddJr.
  • Daniele Ouellet
  • Brendan M. Johnson
  • Daphne Williams
  • Ekaterina Gibiansky
Original Article



Eltrombopag, a thrombopoietin receptor agonist, is being evaluated for the treatment of chemotherapy-induced thrombocytopenia. Due to the delay in platelet response after the administration of eltrombopag or chemotherapy, a modeling and simulation approach was used to optimize the eltrombopag dosing regimen.


Pharmacokinetic (PK) data from 2 studies in healthy subjects and PK and platelet data from a Phase II study in subjects with cancer receiving carboplatin/paclitaxel (where eltrombopag was given 10 days after chemotherapy) were used to develop a nonlinear mixed-effects PK/PD model. Alternative eltrombopag dosing regimens were then simulated.


The PK model was a linear two-compartment model with first-order absorption. Being Asian, female, and >50 years of age were associated with higher eltrombopag exposure. The time course of platelet counts was described by a four-compartment transit model. Carboplatin inhibited platelet precursor production linearly with dose, with increased effect with each cycle of chemotherapy. Eltrombopag stimulated platelet precursor production, proportional to plasma eltrombopag concentration, and stimulation (slope of the concentration effect) was attenuated with each cycle of chemotherapy.


Simulations indicated that eltrombopag administered 5 days before and 5 days after chemotherapy minimizes the decrease and fluctuations in platelet counts relative to other evaluated dosing regimens.


Platelet counts Chemotherapy-induced thrombocytopenia Population pharmacokinetic/pharmacodynamics model Schedule optimization 



Clinical trials described in this work were funded by GlaxoSmithKline. Paul N. Mudd Jr., Daniele Ouellet, and Brendan M. Johnson are GSK employees. Ekaterina Gibiansky and Siobhan Hayes were consultants for GSK.

Supplementary material

280_2013_2150_MOESM1_ESM.doc (33 kb)
Supplementary material 1 (DOC 33 kb)
280_2013_2150_MOESM2_ESM.doc (166 kb)
Supplementary material 2 (DOC 166 kb)
280_2013_2150_MOESM3_ESM.doc (64 kb)
Supplementary material 3 (DOC 64 kb)


  1. 1.
    Promacta prescribing information.
  2. 2.
    Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L et al (2009) Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomized, double-blind, placebo-controlled trial. Lancet 373(9664):641–648PubMedCrossRefGoogle Scholar
  3. 3.
    Bussel J, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B et al (2007) Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357:2237–2247PubMedCrossRefGoogle Scholar
  4. 4.
    McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, TPL102357 Study Group et al (2007) Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 357(22):2227–2236PubMedCrossRefGoogle Scholar
  5. 5.
    Kellum A, Jagiello-Gruszfeld A, Bondarenko IN, Patwardhan R, Messam C, Kamel YM (2010) A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Curr Med Res Opin 26(10):2339–2346PubMedCrossRefGoogle Scholar
  6. 6.
    Vadhan-Raj S, Patel S, Bueso-Ramos C, Folloder J, Papadopolous N, Burgess A, Broemeling LD et al (2003) Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol 21(16):3158–3167PubMedCrossRefGoogle Scholar
  7. 7.
    Jenkins J, Williams D, Deng Y, Collins DA, Kitchen VS (2010) Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis. Eur J Clin Pharmacol 66:67–76PubMedCrossRefGoogle Scholar
  8. 8.
    Matthys G, Park JW, McGuire S, Wire MB, Zhang J, Bowen C et al (2010) Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects. Br J Clin Pharmacol 70(1):24–33PubMedCrossRefGoogle Scholar
  9. 9.
    Williams DD, Peng B, Bailey CK, Wire MB, Deng Y, Park JW et al (2009) Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adults: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther 31:764–776PubMedCrossRefGoogle Scholar
  10. 10.
    Beal SL, Sheiner LB, Boeckmann AJ (eds) NONMEM Users Guides (1989–2006). Icon Development Solutions, Ellicott CityGoogle Scholar
  11. 11.
    Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D (2011) Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol 51(6):842–856PubMedCrossRefGoogle Scholar
  12. 12.
    Gastonguay MR (2011) Full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: a review of methodology and 42 case studies. PAGE 20, Abstr 2229.
  13. 13.
    Harrell FE (2001) Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. Springer, New YorkGoogle Scholar
  14. 14.
    Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Mostafa Kamel Y (2013) Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. BMC Cancer 13:121. doi: 10.1186/1471-2407-13-121
  15. 15.
    Joerger M, Huitema ADR, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E et al (2007) Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 13(21):6410–6418PubMedCrossRefGoogle Scholar
  16. 16.
    Jacqmin P, Snoeck E, van Schaick EA, Gieschke R, Pillai P, Steimer JL et al (2007) Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. J Pharmacokinet Pharmacodyn 34(1):57–85PubMedCrossRefGoogle Scholar
  17. 17.
    Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20(24):4713–4721PubMedCrossRefGoogle Scholar
  18. 18.
    Hayes S, Ouellet D, Zhang J, Wire M, Gibiansky E (2011) Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing. J Clin Pharmacol 51(10):1403–1417PubMedCrossRefGoogle Scholar
  19. 19.
    Dunton CJ (2002) Management of treatment-related toxicity in advanced ovarian cancer. Oncologist 7(Suppl. 5):11–19PubMedCrossRefGoogle Scholar
  20. 20.
    Zhang J, Williams DD, Moore KP (2009) Use of eltrombopag exposure-platelet response relationship for dose optimization in patients with chronic HCV-infection with and without interferon. PAGE 18, Abstr 1494.
  21. 21.
    Chalret du Rieu Q, Fouliard S, White-Koning M, Jacquet A, Kloos I, Depil S, Chatelut E, Chenel M (2012) Semi-mechanistic thrombocytopenia model of a new histone deacetylase inhibitor (HDACi) in development, with a drug-induced apoptosis of megakaryocytes. PAGE 21, Abstr 2503.
  22. 22.
    Meille C, Reddy MB, Walz A, Retout S, Nichols G, Glenn K, Pignatello M, Bottino D, Zhi J, Middleton S, Lavé T (2012) Modified model of drug induced thrombocytopenia efficiently projects safe starting dose in human from preclinical data. PAGE 21, Abstr 2446.
  23. 23.
    Kaefer A, Yang J, Xiong H, Pradhan R, Jaeger M, Noertersheuser P, Mensing S. Evaluation of the long-term decline of platelets following Navitoclax (ABT-263) administration in Cancer Patients with a semi-physiological pharmacodynamic modelGoogle Scholar
  24. 24.
    Retout S, Meille C, Nichols G, Middleton S, Bottino D, Frey N (2012) Prediction of occurrence of thrombocytopenia to select Phase 1b dose and dosing regimen for a selective inhibitor of p53-MDM2 in patients with solid tumors. PAGE 21, Abstr 2391.
  25. 25.
    Wang YM, Krzyzanski W, Doshi S, Xiao JJ, Pérez-Ruixo JJ, Chow AT (2010) Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J 12(4):729–740. doi: 10.1208/s12248-010-9234-9 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Siobhan Hayes
    • 1
  • Paul N. MuddJr.
    • 2
  • Daniele Ouellet
    • 2
  • Brendan M. Johnson
    • 2
  • Daphne Williams
    • 2
    • 4
  • Ekaterina Gibiansky
    • 3
  1. 1.ICON Development SolutionsMarlow, BuckinghamshireUK
  2. 2.GlaxoSmithKlineResearch Triangle ParkUSA
  3. 3.QuantPharm LLCNorth PotomacUSA
  4. 4.Bristol Myers SquibbPrincetonUSA

Personalised recommendations